Citation

Chandan JS, Chandan JK. Lancet 2021; ePub(ePub): ePub.

Copyright

(Copyright © 2021, Elsevier Publishing)

DOI

10.1016/S0140-6736(21)00532-8

PMID

unavailable

Abstract

We are delighted to see Sophie Harman and colleagues advocating the clinical and logistical considerations for the equitable and safe development, delivery, and administration of the COVID-19 vaccine to women. Additionally, there exists an area of gendered vaccine inequality, concerningly neglected to date, relating to the prioritisation of vaccines for survivors of gender-based violence (GBV).

During the pandemic, there has been a surge of GBV, with expected long-term related excess morbidity and mortality. Many countries have yet to implement adequate policies to counter or address this increase. In countries where such measures do exist, such as the UK, these often involve relaxing movement restrictions for those either at risk of or facing GBV. Although we welcome these measures, paradoxically, these strategies are coupled with unconsidered clinical risks for this cohort...

Language: en